# Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

> **NCT06831175** · PHASE2 · RECRUITING · sponsor: **West China Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Adrenal Cortical Carcinoma
- Adrenal Cortical Cancer
- Adrenal Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib
- **DRUG:** mitotane

## Key facts

- **NCT ID:** NCT06831175
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06831175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06831175, "Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06831175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*